HR+/HER2- Metastatic Breast Cancer
The HR+/HER2- Metastatic Breast Cancer pipeline: 105 tracked drugs, 29 approved for this indication.
29 approved / phase 434 Phase 31 Phase 2/38 Phase 221 Phase 1/211 Phase 11 preclinical / unstaged
Compare the share prices of listed companies in HR+/HER2- Metastatic Breast Cancer →
Total attributable cost
$2.6B
$24,600/patient
Drug spend
Not yet sourced
Metastatic (stage IV), de novo and recurrent · US
The HR+/HER2- Metastatic Breast Cancer pipeline
Key trial results for every approved and late-stage drug: HR+/HER2- Metastatic Breast Cancer results by drug.